Survival of adults with acute lymphoblastic leukemia in Germany and the United States.

ABSTRACT:

Background

Adulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood ALL, survival for adults with ALL is poor. Recently, new protocols, including use of pediatric protocols in young adults, have improved survival in clinical trials. Here, we examine population level survival in Germany and the United States (US) to gain insight into the extent to which changes in clinical trials have translated into better survival on the population level.

Methods

Data were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11 cancer registries in Germany. Patients age 15-69 diagnosed with ALL were included. Period analysis was used to estimate 5-year relative survival (RS).

Results

Overall 5-year RS was estimated at 4

SUBMITTER: Pulte D 

PROVIDER: S-EPMC3903479 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature